This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

David L. Dunn, MD; Warren C. Bogard, Jr, PhD; Frank B. Cerra, MD

Arch Surg. 1985;120(1):50-53.

Abstract
• We developed a murine monoclonal antibody (5B10 MAb) that reacted in vitro specifically to lipopolysaccharide (LPS) obtained from Escherichia coli 0111:B4. Enzyme-linked immunosorbent assay (ELISA) titers to a variety of gram-negative bacterial whole cell and LPS antigens demonstrated that this antibody may react with the O antigen portion of 0111:B4 LPS. We then examined the ability of this antibody to protect mice in vivo against a challenge of either viable bacteria or purified LPS. One milligram of 5B10 MAb was administered intraperitoneally (IP) and protected against a lethal challenge of either viable E coli 0111:B4 or 0111:B4 LPS, but no other type of bacterial or LPS challenge. Protection occurred in an antibody dose-dependent manner, and as little as 0.01 mg of 5B10 MAb enhanced survival. We concluded that IP pretreatment with a single MAb would protect against lethal sepsis or endotoxemia in this animal model and that anti-LPS specificity was a sufficient condition for an antibody to protect during bacteremia, confirming the importance of LPS in the pathogenesis of gram-negative bacterial sepsis.

(Arch Surg 1985;120:50-53)

Author Affiliations
From the Department of Surgery, University of Minnesota, Minneapolis (Drs Dunn and Cerra); and Centocor, Malvern, Pa (Dr Bogard).

Footnotes
Accepted for publication Aug 10, 1984.

Read before the Fourth Annual Meeting of the Surgical Infection Society, Montreal, April 30, 1984.

Reprint requests to Mayo Memorial Building, 420 Delaware St SE, Box 242, University of Minnesota, Minneapolis, MN 55455 (Dr Dunn).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cellular and molecular mechanisms underlying LPS-associated myocyte impairment
Tavener and Kubes
Am. J. Physiol. Heart Circ. Physiol. 2006;290:H800-H806.
ABSTRACT | FULL TEXT  

PMX-622 (Polymyxin B-Dextran 70) Does Not Alter In Vitro Activities of 11 Antimicrobial Agents
Fuchs et al.
Antimicrob. Agents Chemother. 1998;42:2765-2767.
ABSTRACT | FULL TEXT  

Inhibition of Splenic Macrophage Tumor Necrosis Factor {alpha} Secretion In Vivo by Antilipopolysaccharide Monoclonal Antibodies
Battafarano et al.
Arch Surg 1994;129:179-186.
ABSTRACT  

Protective Capacity of Polyclonal and Monoclonal Antibodies Directed Against Endotoxin During Experimental Sepsis
Dunn et al.
Arch Surg 1988;123:1389-1393.
ABSTRACT  

Immunotherapy of Gram-negative Bacterial Sepsis: A Single Murine Monoclonal Antibody Provides Cross-Genera Protection
Dunn et al.
Arch Surg 1986;121:58-62.
ABSTRACT